Nordic Nanovector Provides Update on LYMRIT 37-05 Phase 1 DLBCL Trial

Corporate Breaking News

Home : Nordic Nanovector Provides Update on LYMRIT 37-05 Phase 1 DLBCL Trial

Dec 12 2019	Nordic Nanovector Provides Update on LYMRIT 37-05 Phase 1 DLBCL Trial
OSLO, Norway, Dec. 12, 2019 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) reports an update on its LYMRIT 37-05 Phase 1 trial of Betalutin® in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) who are not eligible for autologous stem cell transplantation...


Source:https://www.prnewswire.com:443/news-releases/nordic-nanovector-provides-update-on-lymrit-37-05-phase-1-dlbcl-trial-300973800.html

Related News
» CStone completes registration filing for the Phase I trial of its tumor immune microenvironment modulator CS3005 to enable study initiation in Australia » Students asked to 'set your price for a slave' for assignment